glp 1 microdosing side effects GLP-1 for autoimmune conditions: what the research actually shows Should you microdose GLP-1 drugs?

Mattina C

Study that establishes the efficacy and safety of liraglutide in patients with T2DM and moderate renal impairment, but shows a lack of effect of acute and prolonged therapy with this GLP-1R agonist on eGFR trajectory compared to placebo

Why Insurance Companies Restrict GLP-1 Coverage for Weight Loss Most major insurers classify GLP-1 medications as weight loss drugs rather than metabolic disease treatments, creating a financial barrier for patients seeking appetite suppression therapy

Highlights of Prescribing Information: Trulicity (dulaglutide) injection, for subcutaneous use

The results of the phase 3 trial were published on Wednesday, Sept

February 2, 2026: FDA Published Second Safety Label Change of 2026 for Zepbound Eli Lillys popular weight-loss drug Zepbound had a second safety label update in January 2026